News Capricor’s DMD hope still strong, as it shares financials Capricor shares second quarter financials as FDA reconsiders BLA for DMD therapy deramiocel.
News FDA advisors vote no to Capricor's DMD therapy FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.
News Capricor sues partner Nippon Shinyaku in DMD therapy spat Capricor has filed a lawsuit seeking to split from its commercial partner for Duchenne muscular dystrophy therapy, deramiocel, in the US.
News Capricor files cell therapy for DMD cardiomyopathy with FDA Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.
News Capricor preps phase 3 for Duchenne cell therapy as it seeks... Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.